Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan

被引：0
|
作者：
Boku, N.
Yamazaki, K.
Yamamoto, N.
Takahashi, T.
Fukutomi, A.
Miyazaki, M.
Satoh, T.
Okamoto, I.
Nakagawa, K.
Fukuoka, M.
机构：
[1] Shizuoka Canc Ctr, Shizuoka, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Kinki Univ, Sakai Hosp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14574
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors
    Boku, N.
    Yamazaki, K.
    Fukutomi, A.
    Takahashi, T.
    Yamamoto, N.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 134 - 134
  • [2] Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors
    Wang, Chong
    He, Xiaohui
    Zhou, Bo
    Li, Jing
    Li, Bohua
    Qian, Weizhu
    Hou, Sheng
    Wang, Hao
    Shi, Yuankai
    Guo, Yajun
    MABS, 2011, 3 (01) : 67 - 75
  • [3] A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors.
    Kuenen, Bart
    Witteveen, Petronella Oda
    Ruijter, Rita
    Tjin-A-Ton, Manuel
    Youssoufian, Hagop
    Rowinsky, Eric
    Fox, Floyd
    Wang, Guojun
    Giaccone, Giuseppe
    Emile, Voest
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3448S - 3449S
  • [4] Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer
    Graeven, U
    Vogel, I
    Killing, B
    Hinz, S
    Von Bernstorff, W
    Baselga, J
    Rojo, F
    Tillner, J
    Gropp, P
    Schmiegel, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 210S - 210S
  • [5] Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Strumberg, Dirk
    Schultheis, Beate
    Scheulen, M. E.
    Hilger, R. A.
    Krauss, J.
    Marschner, N.
    Lordick, F.
    Bach, F.
    Reuter, D.
    Edler, L.
    Mross, K.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1138 - 1143
  • [6] Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Dirk Strumberg
    Beate Schultheis
    M. E. Scheulen
    R. A. Hilger
    J. Krauss
    N. Marschner
    F. Lordick
    F. Bach
    D. Reuter
    L. Edler
    K. Mross
    Investigational New Drugs, 2012, 30 : 1138 - 1143
  • [7] A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results.
    Kuenen, B.
    Witteveen, E.
    Ruijter, R.
    Ervin-Haynes, A.
    Tjin-A-ton, M.
    Fox, F.
    Ding, C.
    Giaccone, G.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 126S - 126S
  • [8] Randomized phase I pharmacodynamic study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with advanced EGFR-expressing tumors.
    Trarbach, T
    Mueller, SP
    Schleucher, N
    Dirsch, O
    Statthaus, J
    Beyer, T
    Appel, D
    Rosen, O
    Tillner, J
    Schmid, KW
    Seeber, S
    Vanhoefer, U
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6096S - 6096S
  • [9] Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors
    Schleucher, N
    Tewes, M
    Dirsch, O
    Schmid, KW
    Rosen, O
    Kovar, S
    Seeber, S
    Harstrick, A
    Vanhoefer, U
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S53
  • [10] Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Strumberg, D.
    Schultheis, B.
    Scheulen, M. E.
    Hilger, R. A.
    Krauss, J.
    Marschner, N.
    Lordick, F.
    Bach, F.
    Reuter, D.
    Edler, L.
    Mross, K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (07) : 473 - 475
12345